Anfibatide Treatment in STEMI Patients

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 240 participants.

Also called NCT02495012

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 240 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02495012
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02495012. Randomized; double masking; primary purpose treatment. Start 2015-08 (registry gives no type); primary completion 2016-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Anfibatide Treatment in STEMI Patients
Condition
ST Segment Elevation Myocardial Infarction
Intervention (Drug)
placebo
Intervention (Drug)
Anfibatide
Lead sponsor
Lee's Pharmaceutical Limited (class: industry)

Record details

Record id
cardio:ct-nct02495012
Content hash
0a085365d211a056572d3b6b6193fab9063f1cb8a86ceda1421194cf198c2e26